Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,749 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
Harding JJ, Yang TS, Chen YY, Feng YH, Yen CJ, Ho CL, Huang WT, El Dika I, Akce M, Tan B, Cohen SA, Meyer T, Sarker D, Lee DW, Ryoo BY, Lim HY, Johnston A, Bomalaski JS, O'Reilly EM, Qin S, Abou-Alfa GK. Harding JJ, et al. Among authors: tan b. Cancer. 2021 Dec 15;127(24):4585-4593. doi: 10.1002/cncr.33870. Epub 2021 Aug 20. Cancer. 2021. PMID: 34415578 Free article. Clinical Trial.
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
Fracasso PM, Picus J, Wildi JD, Goodner SA, Creekmore AN, Gao F, Govindan R, Ellis MJ, Tan BR, Linette GP, Fu CJ, Pentikis HS, Zumbrun SC, Egorin MJ, Bellet RE. Fracasso PM, et al. Cancer Chemother Pharmacol. 2009 Feb;63(3):451-8. doi: 10.1007/s00280-008-0756-0. Epub 2008 Apr 15. Cancer Chemother Pharmacol. 2009. PMID: 18414864 Clinical Trial.
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ, Rader JS, Arquette MA, Fleshman JW, Creekmore AN, Goodner SA, Wright LP, Guo Z, Ryan CE, Tao Y, Soares EM, Cai SR, Lin L, Dancey J, Rudek MA, McLeod HL, Piwnica-Worms H. Fracasso PM, et al. Cancer Chemother Pharmacol. 2011 Jun;67(6):1225-37. doi: 10.1007/s00280-010-1410-1. Epub 2010 Aug 8. Cancer Chemother Pharmacol. 2011. PMID: 20694727 Free PMC article. Clinical Trial.
A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
Mamon HJ, Niedzwiecki D, Hollis D, Tan BR, Mayer RJ, Tepper JE, Goldberg RM, Blackstock AW, Fuchs CS; Cancer and Leukemia Group B. Mamon HJ, et al. Cancer. 2011 Jun 15;117(12):2620-8. doi: 10.1002/cncr.25742. Epub 2010 Dec 23. Cancer. 2011. PMID: 21656739 Free PMC article. Clinical Trial.
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma.
Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, Tan B, Hawkins WG. Wang-Gillam A, et al. Among authors: tan b. Invest New Drugs. 2013 Jun;31(3):707-13. doi: 10.1007/s10637-012-9866-y. Epub 2012 Aug 4. Invest New Drugs. 2013. PMID: 22864469 Free PMC article. Clinical Trial.
5,749 results